Cook S, Giovannoni G, Leist T et al.
Presented at the Consortium of Multiple Sclerosis Centers (CMSC) Virtual Poster/Platform Session, August 3, 2020
• Update to the integrated analysis from the Cladribine Tablets clinical trial program (data cut-off October 2018)
• Contains information on the rate of serious treatment-emergent adverse events, infections, lymphopenia and malignancies
• Also contains post-approval safety data from the first patients to receive commercial Cladribine Tablets, cumulative to January 2020 – including information on cases of COVID-19